Birnam Oak Advisors LP Makes New Investment in Amedisys, Inc. (NASDAQ:AMED)

Birnam Oak Advisors LP acquired a new position in shares of Amedisys, Inc. (NASDAQ:AMED) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 174,383 shares of the health services provider’s stock, valued at approximately $15,832,000. Amedisys comprises 7.7% of Birnam Oak Advisors LP’s investment portfolio, making the stock its 6th biggest holding. Birnam Oak Advisors LP owned approximately 0.53% of Amedisys at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in AMED. Blue Trust Inc. increased its holdings in shares of Amedisys by 55.1% in the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock valued at $34,000 after acquiring an additional 124 shares during the last quarter. HBW Advisory Services LLC bought a new stake in shares of Amedisys in the 4th quarter valued at approximately $38,000. Versant Capital Management Inc increased its holdings in shares of Amedisys by 68.5% in the 4th quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock valued at $41,000 after acquiring an additional 183 shares during the last quarter. KBC Group NV bought a new stake in shares of Amedisys in the 3rd quarter valued at approximately $63,000. Finally, Vestcor Inc bought a new stake in shares of Amedisys in the 4th quarter valued at approximately $73,000. 94.36% of the stock is currently owned by institutional investors.

Amedisys Trading Up 0.1 %

NASDAQ:AMED opened at $92.64 on Tuesday. Amedisys, Inc. has a 12-month low of $82.15 and a 12-month high of $98.95. The firm has a market capitalization of $3.04 billion, a P/E ratio of 36.76, a P/E/G ratio of 1.78 and a beta of 0.76. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The business has a 50 day simple moving average of $92.16 and a 200 day simple moving average of $92.71.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.09). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The business had revenue of $598.05 million for the quarter, compared to analyst estimates of $602.38 million. Equities research analysts predict that Amedisys, Inc. will post 4.4 EPS for the current year.

Analysts Set New Price Targets

Separately, Stephens restated an “equal weight” rating and set a $101.00 price objective on shares of Amedisys in a research report on Tuesday, March 4th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $100.75.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.